Deals: Page 82
-
Chiasma raising $56M to develop acromegaly drug—without Roche
Last August, Roche backed out of a $600 million co-development deal with Chiasma. But the company pledged to move forward.
By Nicole Gray • Jan. 5, 2015 -
It's over: Teva and OncoGenex dissolve custirsen cancer partnership
A partnership initiated between Teva and OncoGenex in 2009 has been scuttled as Teva backs out of a deal to co-develop a prostate cancer drug.
By Nicole Gray • Dec. 31, 2014 -
Novo searching for successor to CEO Sørensen, who has big shoes to fill
Lars Rebien Sørensen has overseen tremendous growth at Novo Nordisk over his long tenure. But the Novo team reportedly isn't too worried about a transition to a new chief.
By Sy Mukherjee • Dec. 29, 2014 -
J&J investing $125M up front for MacroGenics' blood cancer drug
With an additional $575 million in prospective milestone fees.
By Nicole Gray • Dec. 23, 2014 -
Vanda, Novartis reach settlement in schizophrenia drug licensing spat
Novartis will transfer all U.S. and Canadian rights for Fanapt (iloperdione) back to Vanda Pharmaceuticals, among other provisions of the settlement.
By Nicole Gray • Dec. 23, 2014 -
HHS's BARDA grants $30M Ebola vax development contract to NewLink
All of the clinical development, testing, and manufacturing of the rVSV-EBOV vaccine will be handled by BioProtection Systems—a subsidiary of NewLink.
By Nicole Gray • Dec. 23, 2014 -
Actavis considering Almirall acquisition to expand European foothold
After its $66 billion deal with Allergan, Actavis is considering new takeover targets, including Almirall, which is based in Spain and could provide a basis for growth in the European market.
By Nicole Gray • Dec. 22, 2014 -
AbbVie pins hopes for first major approval in 10 years on hep C drug
AbbVie is in desperate need of diversification, because it relies on just one drug, Humira, for 63% of its profits. Could its new hep C treatment be the answer?
By Nicole Gray • Dec. 19, 2014 -
Actavis reveals post-merger management plans: Saunders to stay as CEO
Actavis dished on what the company's management structure will look like after its Allergan acquisition is complete.
By Nicole Gray • Dec. 18, 2014 -
Report: Shire still hunting for a deal, maybe with NPS Pharma
Just two months after a massive anticipated $55 billion deal with AbbVie fell apart, Shire is reportedly considering a bid for NJ-based NPS Pharmaceuticals.
By Nicole Gray • Dec. 18, 2014 -
Google Ventures ventures more aggressively into healthcare, life sciences
In 2014, more than one-third of the venture capital invested by Google Ventures went into healthcare and life sciences start-ups—a 9% increase from 2012 and 2013.
By Nicole Gray • Dec. 17, 2014 -
Pfizer, OPKO reach growth hormone drug pact worth up to $570M
Pfizer and OPKO Health are collaborating on a medication that will address growth-hormone deficiency—without the inconvenience of daily injections.
By Nicole Gray • Dec. 16, 2014 -
The other victims of scuttled AbbVie-Shire deal? Big banks
The fallout from the scuttled $55 billion deal is piling up as it becomes apparent that many banks and hedge funds had big positions in Shire.
By Nicole Gray • Dec. 16, 2014 -
Abbott closes Veropharm deal amidst US-Russia political tension
Abbott has completed a deal to buy Veropharma from billionaire Roman Avdeev for $305 million, in spite of ongoing political tensions between the West and Russia.
By Nicole Gray • Dec. 15, 2014 -
After failed Allergan offensive, Valeant finally taking break from M&A focus
After an epic struggle that culminated in Valeant failing to acquire Allergan, the Valeant is reportedly regrouping and taking a break from acquisitions to focus on debt reduction.
By Nicole Gray • Dec. 10, 2014 -
A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents
One day after Merck announced a $9.5B acquisition of antibiotics powerhouse Cubist, a federal judge invalidated four of the five patents on the company's flagship Cubicin.
By Nicole Gray • Dec. 10, 2014 -
FDA: A defined biosimlar pathway is coming—soon
The FDA is emphasizing that, despite the lack of a formal pathway, a biosimilar can still be approved.
By Nicole Gray • Dec. 8, 2014 -
Merck to buy antibiotics powerhouse Cubist for $9.5 billion
With this acquisition, Merck will be getting a strong portfolio and pipeline of mega-potent antibiotics to shore up its existing infectious diseases franchise.
By Nicole Gray • Dec. 8, 2014 -
GSK reverses course, retracts plan to sell older drugs
Last month, BioPharma Dive reported on potential bidders for GSK's portfolio of mature drugs. There is no winner—the deal is off.
By Nicole Gray • Dec. 5, 2014 -
Actavis to lay off 200 workers in California
Effective January 2, Actavis will lay off 200 workers in Corona, California.
By Nicole Gray • Dec. 4, 2014 -
Patent cliff ahead: Otsuka to buy Avanir for $3.5B and a slate of new products
With the looming patent expiration of its high-earning schizophrenia drug Abilify (aripiprazole), Otsuka is acquiring a company with a strong neurologic drug franchise.
By Nicole Gray • Dec. 3, 2014 -
A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal
Despite the optimism surrounding the R&D partnership between J&J and Astellas in 2012, J&J is opting out of the deal just as the rheumatoid arthritis drug it supported moves into phase III.
By Nicole Gray • Dec. 3, 2014 -
Meet the healthcare and pharma industry vet who will be Teva's next chairman
On January 1, 2015, Teva board member Yitzhak Peterburg will become Chairman of the board as Phillip Frost, who has been called controversial, steps down.
By Nicole Gray • Dec. 2, 2014 -
Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations
Gilead and Mylan are staying true to the theme for this year's World AIDS Day: "Focus, Partner, Achieve: An AIDS-Free Generation."
By Nicole Gray • Dec. 2, 2014 -
Done deal: Pfizer completes acquistion of Baxter's vaccines
The most valuable additions are vaccines that protect against meningitis and tick-borne encephalitis.
By Nicole Gray • Dec. 2, 2014
Previous
